Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).
2020
Background:Natalizumab is a highly efficacious therapy for relapsing–remitting multiple sclerosis (RRMS). Patients who discontinue natalizumab may experience return of MS disease activity.Objective...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
25
References
3
Citations
NaN
KQI